Morgan Cheatham takes charge of healthcare innovation at Breyer Capital
- Morgan Cheatham has joined Breyer Capital as Partner and Head of Healthcare and Life Sciences, focusing on healthcare AI and biomedicine.
- Prior to this role, he was Vice President at Bessemer Venture Partners, where he led healthcare AI investments.
- Cheatham's appointment marks a significant effort by Breyer Capital to revolutionize healthcare delivery through technology.
In March 2025, Morgan Cheatham, a noted physician-informaticist and former Vice President at Bessemer Venture Partners, joined Breyer Capital to lead its healthcare and life sciences strategy. Cheatham, known for his expertise in healthcare AI, aims to drive significant advancements in biomedicine and precision medicine. His journey in venture capital began after he met Jim Breyer at Brown University, where they shared a vision for integrating computational methods into healthcare. Breyer Capital is recognized for its investments in AI and computational healthcare, and Cheatham's addition further strengthens the firm's commitment to transforming the healthcare landscape. Cheatham’s professional background includes sourcing over a dozen early-stage investments at Bessemer, reflecting his ability to identify transformative opportunities. His prior involvement in founding the Editorial Team at NEJM AI showcases his ongoing commitment to advancing the field of medicine through technology. This strategic move by Breyer Capital aligns with its history of making bold investments in AI, quantum computing, and healthcare-driven tech, with a portfolio featuring significant companies like Meta and Spotify. By bringing Cheatham into the fold, Breyer Capital is reaffirming its belief that healthcare delivery and technology are on a converging path. Jim Breyer emphasized Cheatham’s distinctive qualifications by stating, “He brings clinical insight, venture experience, and a sharp eye for transformative science.” This sentiment not only underscores Cheatham's competence but also emphasizes the high expectations surrounding his role in reshaping healthcare. Furthermore, Cheatham's collaboration with Harvard Medical School’s Department of Biomedical Informatics to advance AI-powered precision medicine signifies a vital partnership aimed at bridging the gap between technological advancements and healthcare delivery. By focusing on software-driven platforms and computational medicine, Breyer Capital envisions a future where healthcare infrastructure can be fundamentally transformed, catering to evolving clinical needs. Cheatham’s leadership will be pivotal as the landscape of healthcare continues to evolve rapidly due to technological advancements.